Related Experiment Video
Updated: Jul 25, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Glucose intolerance: the hidden danger in hypertensives!
1Hypertension Clinic and the Cardiac Research Unit, Central Middlesex Hospital, London, UK. majeed.salmasi@nwlh.nhs.uk
Insights
Systemic hypertension and glucose intolerance significantly increase cardiovascular risk. Early detection of unrecognised glucose metabolism abnormalities in hypertensive patients via oral glucose tolerance tests is crucial for effective management and risk assessment.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Systemic hypertension and abnormal glucose metabolism are independent cardiovascular risk factors.
- Their coexistence exacerbates cardiovascular morbidity and mortality.
- Both conditions contribute to arterial stiffness and cardiac remodeling, including left ventricular hypertrophy and diastolic dysfunction.
Purpose of the Study:
- To highlight the high prevalence of unrecognised glucose metabolism abnormalities in hypertensive patients.
- To emphasize the inadequacy of current screening methods (fasting plasma glucose, HbA1c) for detecting these abnormalities.
- To advocate for the routine use of oral glucose tolerance tests in hypertensive patients.
Main Methods:
- Analysis of oral glucose tolerance test (OGTT) results in patients with systemic hypertension.
- Comparison of OGTT findings with fasting plasma glucose and glycated haemoglobin levels.
- Assessment of cardiovascular risk associated with coexisting hypertension and glucose intolerance.
Main Results:
- 58% of hypertensive patients without a known cardiac history or diabetes have unrecognised glucose metabolism abnormalities (diabetes or impaired glucose tolerance).
- Fasting plasma glucose and HbA1c lack sensitivity for diagnosing diabetes and cannot identify impaired glucose tolerance in this population.
- Underestimation of cardiovascular risk occurs when glucose intolerance is not identified.
Conclusions:
- Oral glucose tolerance tests are essential for early detection of glucose metabolism abnormalities in hypertensive patients.
- Early identification enables appropriate management and primary preventative measures.
- Routine OGTT screening in hypertension clinics is recommended to accurately assess cardiovascular risk.
Abstract:
Both systemic hypertension and abnormalities of glucose metabolism are independent recognised risk factors for the development of cardiovascular morbidity and mortality, but their effects become additive when they coexist. Hypertension and glucose intolerance increase arterial stiffness and lead to cardiac structural and functional changes such as left ventricular hypertrophy and diastolic dysfunction of the left ventricle. Oral glucose tolerance tests have shown that 58% of patients with systemic hypertension who have no cardiac history and who are not known to have diabetes, suffer from unrecognised abnormalities of glucose metabolism i.e. either diabetes or impaired glucose tolerance. Using the fasting plasma glucose level and/or glycated haemoglobin concentration to diagnose glucose intolerance in patients with systemic hypertension is insufficient because of their low sensitivity for the diagnosis of diabetes and their inability to identify impaired glucose tolerance. It is important to recognise abnormalities of glucose metabolism early in patients with systemic hypertension in order to implement appropriate management and avoid further complications. Failure to identify glucose intolerance results in serious underestimation of the cardiovascular risk of these patients and denies patients primary preventative measures, which are based on risk assessment. All patients referred to Hypertension Clinics for the management of raised blood pressure should therefore be investigated by glucose tolerance test.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications
Hypoglycemia and Glucagon
Hypoglycemia
Hyperglycemia

